GMAB Genmab A/S

50.60USD-1.46%Mkt Cap: 31.20B USDP/E: 42.88

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with rel…

Institutional holders20 on file

Key Statistics

Company
Market Cap31.20B USD
Enterprise Value35.83B USD
Revenue (TTM)4.30B USD
Gross Profit3.48B USD
Net Income (TTM)963.00M USD
Revenue/Share6.99 USD
Last Price50.60 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees3.2K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)42.88
P/E (Forward)32.03
PEG4.64
EV/EBITDA26.42
EV/Revenue8.34
P/S7.26
P/B5.06
EPS (TTM)1.17 USD
EPS (Forward)1.58 USD
52W Range
23.6274% of range59.97
52W High59.97 USD
52W Low23.62 USD
Profitability
Gross Margin93.60%
Oper. Margin30.63%
EBITDA Margin31.56%
Profit Margin25.89%
ROE16.47%
ROA7.48%
ROIC10.46%
ROCE10.92%
Growth
Revenue Growth16.10%
Earnings Growth-14.70%
Cash Flow & Leverage
Operating CF1.19B USD
CapEx (TTM)55.00M USD
FCF Margin19.90%
FCF Yield2.74%
Net Debt3.33B USD
Net Debt/EBITDA2.45
Net Debt/FCF3.89
Balance Sheet
Debt/Equity0.93
Current Ratio2.45
Quick Ratio2.43
Book Value/Sh10.01 USD
Cash/Share2.96 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split5:1
Split DateMay 1, 2018
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)65.01 USD
Upside (mean)+28.5%
Target Range48.00 USD – 80.00 USD
48.00+28.5% to mean80.00
# Analysts11
Ownership
Shares Out.616.59M
Float589.60M
Insiders0.00%
Institutions22.17%
Short Interest
Short Ratio1.5d
Short % Float1.59%
Short % Out.1.57%
Shares Short9.66M
Short (prev mo.)6.06M
Technical
SMA 5042.24 (+19.8%)
SMA 20031.82 (+59.0%)
Beta0.52
S&P 52W Chg12.00%
Avg Vol (30d)5.42M
Avg Vol (10d)4.24M
Technical Indicators
RSI (14)55.3
MACD2.3864
MACD Signal3.3658
MACD Hist.-0.9794
BB Upper59.72 USD
BB Middle52.77 USD
BB Lower45.82 USD
BB Width26.33%
ATR (14)2.034 USD
Vol Ratio (20d)0.44x

About Genmab (NASDAQ: GMAB)

›

Genmab (NASDAQ: GMAB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3,244 employees.

The shares were at 50.60 USD on 20 November 2026, up 66.1% over 52 weeks. Its 52-week range is 23.62 USD to 59.97 USD: the price is 15.6% below the high and 114.2% above the low.

At a market capitalisation of 31.20B USD, it trades at 42.9 times trailing earnings and 32.0 times forward earnings. The median trailing P/E of its 12 largest Biotechnology peers is 32.6, a premium of 32% for GMAB.

Genmab reports return on equity of 16.5%, an operating margin of 30.6% and revenue up 16.1% year over year.

Its debt exceeds its cash by 3.33B USD, a debt-to-equity ratio of 0.93. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 65.01 USD is 28.5% above the current price. The next earnings report is expected on 16 February 2027.